Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fulcrum Therapeutics (FULC) EBIT (2019 - 2026)

Fulcrum Therapeutics (FULC) has disclosed EBIT for 7 consecutive years, with -$22.7 million as the latest value for Q4 2025.

  • Quarterly EBIT fell 16.8% to -$22.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$84.8 million through Dec 2025, down 287.13% year-over-year, with the annual reading at -$84.8 million for FY2025, 287.13% down from the prior year.
  • EBIT for Q4 2025 was -$22.7 million at Fulcrum Therapeutics, down from -$21.9 million in the prior quarter.
  • The five-year high for EBIT was $52.5 million in Q2 2024, with the low at -$34.2 million in Q2 2022.
  • Average EBIT over 5 years is -$20.5 million, with a median of -$24.0 million recorded in 2021.
  • The sharpest move saw EBIT surged 292.33% in 2024, then plummeted 137.75% in 2025.
  • Over 5 years, EBIT stood at -$23.6 million in 2021, then decreased by 18.74% to -$28.0 million in 2022, then dropped by 0.07% to -$28.0 million in 2023, then surged by 30.59% to -$19.4 million in 2024, then decreased by 16.8% to -$22.7 million in 2025.
  • According to Business Quant data, EBIT over the past three periods came in at -$22.7 million, -$21.9 million, and -$19.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.